Justine L. Lam

2.0k total citations
16 papers, 454 citations indexed

About

Justine L. Lam is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Justine L. Lam has authored 16 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Justine L. Lam's work include Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Justine L. Lam is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Justine L. Lam collaborates with scholars based in United States, Switzerland and United Kingdom. Justine L. Lam's co-authors include Leslie Z. Benet, Hideaki Okochi, Yong Huang, Sarah Shugarts, Eric Y. Zhang, Ying Jiang, Tao Zhang, Bill J. Smith, Allison Vitsky and Gina M. Yanochko and has published in prestigious journals such as Cancer Research, Journal of Pharmacology and Experimental Therapeutics and Toxicological Sciences.

In The Last Decade

Justine L. Lam

15 papers receiving 451 citations

Peers

Countries citing papers authored by Justine L. Lam

Since Specialization

Citations

This map shows the geographic impact of Justine L. Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justine L. Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justine L. Lam more than expected).

Fields of papers citing papers by Justine L. Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justine L. Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justine L. Lam. The network helps show where Justine L. Lam may publish in the future.

Co-authorship network of co-authors of Justine L. Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Justine L. Lam. A scholar is included among the top collaborators of Justine L. Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justine L. Lam. Justine L. Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Abstract 390: ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors 2025 ·Cancer Research ·(unknown), Alexei Brooun, Justine L. Lam, (unknown), (unknown), (unknown), Jae Hyun Bae, Bingzhen Lin, (unknown), (unknown), (unknown), (unknown), Dawei Xuan, (unknown)	0
2	Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF‐06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies 2020 ·The Journal of Clinical Pharmacology ·Daria Stypinski, (unknown), Justine L. Lam, Alfin D. N. Vaz, Theodore R. Johnson, (unknown), Yazdi K. Pithavala	15
3	Metabolism, excretion and pharmacokinetics of [¹⁴C]glasdegib (PF-04449913) in healthy volunteers following oral administration 2016 ·Xenobiotica ·Justine L. Lam, Alfin D. N. Vaz, Brian Hee, Yali Liang, Xin Yang, M. Naveed Shaik	21
4	Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models 2015 ·Cancer Research ·Ping Wei, Ming Qiu, Nathan Lee, Joan Cao, Hui Wang, Konstantinos Tsaparikos, (unknown), (unknown), Justine L. Lam, Maruja E. Lira, Goldie Y.L. Lui, James C.H. Hardwick, Valeria R. Fantin, Paul A. Rejto, Tod Smeal	4
5	Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase 2014 ·Drug Metabolism and Disposition ·Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal, Paolo Vicini	15
6	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal, Paolo Vicini	19
7	Abstract 1958: Interrogating hedgehog pathway and smoothened inhibition by PF-04449913 in patient-derived acute myeloid leukemia models 2014 ·Cancer Research ·Amy Jackson-Fisher, Pamela Whalen, Mark Elliott, Melissa McMahon, Enhong Chen, Xianxian Zheng, Mark Ozeck, Donghui Huang, Paul D. Lira, Joseph Lee, Cathy Zhang, Justine L. Lam, Mary E. Spilker, Shibing Deng, Patrick B. Lappin, (unknown), Cynthia Heinlein, (unknown), Karen R. McLachlan, Todd VanArsdale	5
8	Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction 2013 ·Toxicological Sciences ·Gina M. Yanochko, Allison Vitsky, Jonathan R. Heyen, Brad Hirakawa, Justine L. Lam, (unknown), Tim Nichols, (unknown), (unknown), Eileen Blasi	58
9	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin 2013 ·Drug Metabolism and Disposition ·Manthena V. S. Varma, Jian Lin, Yi‐An Bi, Charles J. Rotter, Odette A. Fahmi, Justine L. Lam, Ayman El‐Kattan, Theunis C. Goosen, Yurong Lai	47
10	Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models. 2013 ·Molecular Cancer Therapeutics ·Helen Y. Zou, (unknown), Qiuhua Li, (unknown), (unknown), Hui Wang, Konstantinos Tsaparikos, Sergei Timofeevski, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Hovhannes J. Gukasyan, Nathan Lee, Ted W. Johnson, Valeria R. Fantin, Tod Smeal	9
11	Effective Targeting of Hedgehog Signaling in a Medulloblastoma Model with PF-5274857, a Potent and Selective Smoothened Antagonist That Penetrates the Blood–Brain Barrier 2011 ·Molecular Cancer Therapeutics ·(unknown), Mary E. Spilker, Justine L. Lam, Bernadette Pascual, Darian M. Bartkowski, (unknown), Amy H. Yang, (unknown), Meirong Xu, Peter A. Wells, Simon Planken, Sajiv K. Nair, Shaoxian Sun	44
12	Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models 2011 ·Cancer Research ·Amy Jackson-Fisher, Melissa McMahon, Justine L. Lam, Chunze Li, Lars D. Engstrom, Konstantinos Tsaparikos, David J. Shields, Douglas D. Fang, Maruja E. Lira, Zhou Zhu, Michael Robbins, Richard B. Schwab, Michael J. Munchhof, Todd VanArsdale	8
13	Expression and Functional Analysis of Hepatic Cytochromes P450, Nuclear Receptors, and Membrane Transporters in 10- and 25-Week-Old db/db Mice 2010 ·Drug Metabolism and Disposition ·Justine L. Lam, Ying Jiang, Tao Zhang, Eric Y. Zhang, Bill J. Smith	36
14	IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY 2006 ·Drug Metabolism and Disposition ·Justine L. Lam, Hideaki Okochi, Yong Huang, Leslie Z. Benet	67
15	Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Justine L. Lam, Sarah Shugarts, Hideaki Okochi, Leslie Z. Benet	30
16	HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES 2004 ·Drug Metabolism and Disposition ·Justine L. Lam, Leslie Z. Benet	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact